Pre and Postoperative Management of Total Thyroidectomy

Preoperative Management

The American Academy of Otolaryngology-Head and Neck Surgery recommends that all patients undergoing total thyroidectomy should receive preoperative laryngeal examination to assess vocal fold mobility, and postoperative examination should be performed between 2 weeks and 2 months to detect recurrent laryngeal nerve injury, which occurs in approximately 9.8% of cases 1, 2, 3
Preoperative laryngoscopy should be performed on all patients to establish baseline vocal fold mobility, particularly those with voice changes, thyroid malignancy, or invasive disease 1, 2, 4
Flexible laryngoscopy is preferred over mirror examination as it allows video recording, evaluation during speech tasks, and detection of subtle motion abnormalities 1, 2
Preoperative vocal fold paralysis occurs in 6.5% of patients and strongly suggests invasive malignancy (>70% in invasive disease vs 0.3% in noninvasive disease), which fundamentally changes surgical planning 2, 4
Document baseline thyroid function tests (TSH, FT3, FT4) as these guide postoperative hormone replacement dosing 5
For suspected medullary thyroid carcinoma (MTC): obtain baseline serum calcitonin, CEA, calcium, and plasma/urine metanephrines to screen for pheochromocytoma 5, 6
For differentiated thyroid cancer: perform neck ultrasound to assess lymph node involvement and determine extent of surgery 7
Preoperative risk stratification determines whether prophylactic central neck dissection is warranted 7

Place a post-thyroid surgery emergency box at bedside containing wound opening supplies during the entire postoperative period, including transfers 8
Emergency front-of-neck airway equipment (scalpel, bougie, tracheal tube) must be readily available on the ward 8
Minimum monitoring includes wound inspection, early warning scores, pain scoring, and vigilance for subtle signs: agitation, anxiety, breathing difficulty, or discomfort 8
Postoperative hematoma occurs in 0.45%-4.2% of cases and can cause rapid airway obstruction even with small volumes 8
If airway compromise from hematoma is suspected, use the SCOOP approach at bedside: Skin exposure, Cut sutures, Open skin, Open muscles (superficial and deep layers), Pack wound 8
Monitor for hypocalcemia, which occurs temporarily in approximately 8.1% of patients after total thyroidectomy 7
Check serum calcium levels postoperatively as hypoparathyroidism is a common complication requiring calcium and vitamin D supplementation 7
Systematically assess voice between 2 weeks and 2 months postoperatively using patient-reported outcomes or formal voice evaluation 3
Examine vocal fold mobility or refer for laryngoscopy in any patient with voice change after surgery 3
Temporary vocal fold paralysis occurs in 9.8% of patients; permanent paralysis occurs in 2.5%-4.3% 3

For differentiated thyroid cancer: initiate levothyroxine (L-T4) immediately after surgery for both replacement and TSH suppression 5, 7
TSH suppression targets based on risk stratification:
Check thyroid function tests (FT3, FT4, TSH) at 2-3 months post-surgery to verify adequate L-T4 dosing 5
For medullary thyroid cancer: do not use TSH suppression therapy—MTC cells lack TSH receptors and do not respond to TSH stimulation 5, 6
Maintain TSH in normal range with replacement-dose levothyroxine only 5, 6
High-risk differentiated thyroid cancer patients: RAI ablation is indicated 5
Low-risk patients (papillary microcarcinoma): RAI is NOT indicated 5, 9
Intermediate-risk patients: individualize decision based on specific risk factors 5
Medullary thyroid cancer: RAI is contraindicated as MTC does not concentrate iodine 6

For differentiated thyroid cancer: at 6-12 months: physical examination, neck ultrasound, basal and rhTSH-stimulated serum thyroglobulin measurement with or without diagnostic whole body scan 5
For patients free of disease: annual physical examination, basal serum thyroglobulin on L-T4 therapy, and neck ultrasound 5
Dynamic risk stratification should be performed during follow-up, reclassifying patients as excellent response, biochemical incomplete, structural incomplete, or indeterminate based on imaging and thyroglobulin levels 7
For medullary thyroid cancer: measure serum calcitonin every 6 months for first 2-3 years, then annually 5, 6
Calculate calcitonin and CEA doubling times from sequential measurements to assess disease progression 6
If post-surgery calcitonin is undetectable after provocative testing, repeat calcitonin every 6 months for 2-3 years, then annually 5
If basal calcitonin >150 pg/ml: screen for distant metastases with comprehensive imaging 5, 6
If calcitonin <150 pg/ml: limit evaluation to careful neck ultrasound 5